Urogen Pharma (NASDAQ:URGN) Hits New 12-Month High - Here's What Happened

Urogen Pharma (NASDAQ:URGN - Get Free Report)'s stock price reached a new 52-week high on Wednesday . The stock traded as high as $17.28 and last traded at $16.96, with a volume of 2118088 shares changing hands. The stock had previously closed at $15.46.

Analyst Ratings Changes

Several research firms recently weighed in on URGN. The Goldman Sachs Group set a $16.00 target price on shares of Urogen Pharma and gave the company a "neutral" rating in a research note on Friday, June 13th. Oppenheimer set a $31.00 target price on shares of Urogen Pharma and gave the company a "buy" rating in a research note on Friday, June 13th. D. Boral Capital reissued a "buy" rating and issued a $25.00 target price on shares of Urogen Pharma in a research note on Monday, July 7th. HC Wainwright reissued a "buy" rating and issued a $50.00 target price on shares of Urogen Pharma in a research note on Tuesday, July 8th. Finally, Scotiabank reissued an "outperform" rating on shares of Urogen Pharma in a research note on Friday, June 13th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Urogen Pharma currently has an average rating of "Buy" and an average target price of $32.86.

Urogen Pharma Price Performance

The stock's 50-day simple moving average is $11.17 and its 200 day simple moving average is $10.73. The stock has a market capitalization of $875.49 million, a P/E ratio of -5.96 and a beta of 1.02.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 150.68%. The company had revenue of $20.25 million for the quarter, compared to the consensus estimate of $22.71 million. As a group, analysts expect that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Urogen Pharma news, insider Mark Schoenberg sold 5,162 shares of Urogen Pharma stock in a transaction on Monday, June 9th. The shares were sold at an average price of $7.37, for a total transaction of $38,043.94. Following the completion of the transaction, the insider directly owned 153,378 shares of the company's stock, valued at $1,130,395.86. The trade was a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Urogen Pharma

A number of institutional investors have recently modified their holdings of URGN. Charles Schwab Investment Management Inc. boosted its position in shares of Urogen Pharma by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company's stock valued at $996,000 after acquiring an additional 3,024 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of Urogen Pharma in the fourth quarter valued at about $59,000. Wellington Management Group LLP boosted its position in shares of Urogen Pharma by 7.0% in the fourth quarter. Wellington Management Group LLP now owns 146,953 shares of the company's stock valued at $1,565,000 after acquiring an additional 9,653 shares during the period. Alliancebernstein L.P. boosted its position in shares of Urogen Pharma by 751.5% in the fourth quarter. Alliancebernstein L.P. now owns 199,259 shares of the company's stock valued at $2,122,000 after acquiring an additional 175,859 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Urogen Pharma by 1.4% in the fourth quarter. Geode Capital Management LLC now owns 461,902 shares of the company's stock valued at $4,919,000 after acquiring an additional 6,265 shares during the period. Institutional investors own 91.29% of the company's stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.